Probiotic and commensal gut microbial therapies in multiple sclerosis and its animal models: a comprehensive review

References

• Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple sclerosis: mechanisms and immunotherapy. Neuron. 2018;97(4):742–27. doi:10.1016/j.neuron.2018.01.021.
   Google Scholar
• Robertson D, Moreo N. Disease-modifying therapies in multiple sclerosis: overview and treatment considerations. Fed Pract. 2016;33:28–34.
   Google Scholar
• Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler. 2020;26(14):1816–1821. doi:10.1177/1352458520970841
   Google Scholar
• Förster M, Küry P, Aktas O, Warnke C, Havla J, Hohlfeld R, Mares J, Hartung H-P, Kremer D. Managing risks with immune therapies in multiple sclerosis. Drug Saf. 2019;42(5):633–647. doi:10.1007/s40264-018-0782-8
   Google Scholar
• Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F, Tomassini V, Wardle M, Pickersgill T, Robertson N, Tallantyre E. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76(5):536. doi:10.1001/jamaneurol.2018.4905
   Google Scholar
• Yano H, Gonzalez C, Healy BC, Glanz BI, Weiner HL, Chitnis T. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: effect on clinical and MRI outcomes. Mult Scler Relat Disord. 2019;35:119–127. doi:10.1016/j.msard.2019.07.021.
   Google Scholar
• Baroncini D, Zaffaroni M, Moiola L, Lorefice L, Fenu G, Iaffaldano P, Simone M, Fanelli F, Patti F, D’Amico E, et al. Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: a multicentre, Italian, retrospective, observational study. Mult Scler. 2019;25(3):399–407. doi:10.1177/1352458518754364
   Google Scholar
• Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing–remitting multiple sclerosis. Mult Scler. 2009;15(1):50–58. doi:10.1177/1352458508096687.
   Google Scholar
• Hua LH, Harris H, Conway D, Thompson NR. Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60. Mult Scler Relat Disord. 2019;30:252–256. doi:10.1016/j.msard.2019.02.028.
   Google Scholar
• Marrie RA. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol. 2004;3(12):709–718. doi:10.1016/S1474-4422(04)00933-0.
   Google Scholar
• Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010;9(7):727–739. doi:10.1016/S1474-4422(10)70094-6.
   Google Scholar
• Boziki MK, Kesidou E, Theotokis P, Mentis A-FA, Karafoulidou E, Melnikov M, Sviridova A, Rogovski V, Boyko A, Grigoriadis N. Microbiome in multiple sclerosis: where are we, what we know and do not know. Brain Sci. 2020;10(4):234. doi:10.3390/brainsci10040234
   Google Scholar
• Galland L. The gut microbiome and the brain. J Med Food. 2014;17(12):1261–1272. doi:10.1089/jmf.2014.7000.
   Google Scholar
• Camara-Lemarroy CR, Metz LM, Yong VW. Focus on the gut-brain axis: multiple sclerosis, the intestinal barrier and the microbiome. WJG. 2018;24(37):4217–4223. doi:10.3748/wjg.v24.i37.4217.
   Google Scholar
• Ochoa-Repáraz J, Mielcarz DW, Ditrio LE, Burroughs AR, Foureau DM, Haque-Begum S, Kasper LH. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J Immunol. 2009;183(10):6041–6050. doi:10.4049/jimmunol.0900747
   Google Scholar
• Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016;7(1):12015. doi:10.1038/ncomms12015
   Google Scholar
• Camara-Lemarroy CR, Metz L, Meddings JB, Sharkey KA, Wee Yong V. The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics. Brain. 2018;141(7):1900–1916. doi:10.1093/brain/awy131.
   Google Scholar
• Miyake S, Kim S, Suda W, Oshima K, Nakamura M, Matsuoka T, Chihara N, Tomita A, Sato W, Kim S-W, et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to Clostridia XIVa and IV clusters. Wilson BA, ed. PLoS ONE. 2015;10(9):e0137429. doi:10.1371/journal.pone.0137429
   Google Scholar
• Berer K, Gerdes LA, Cekanaviciute E, Jia X, Xiao L, Xia Z, Liu C, Klotz L, Stauffer U, Baranzini SE, et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci USA. 2017;114(40):10719–10724. doi:10.1073/pnas.1711233114
   Google Scholar
• Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Paz Soldan MM, Luckey DH, Marietta EV, Jeraldo PR, Chen X, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 2016;6(1):28484. doi:10.1038/srep28484
   Google Scholar
• Chang C-J, Lin T-L, Tsai Y-L, Wu T-R, Lai W-F, Lu C-C, Lai H-C. Next generation probiotics in disease amelioration. J Food Drug Anal. 2019;27(3):615–622. doi:10.1016/j.jfda.2018.12.011
   Google Scholar
• Xu H, Liu M, Cao J, Li X, Fan D, Xia Y, Lu X, Li J, Ju D, Zhao H. The dynamic interplay between the gut microbiota and autoimmune diseases. J Immunol Res. 2019;2019:1–14. doi:10.1155/2019/7546047
   Google Scholar
• Smallwood TB, Giacomin PR, Loukas A, Mulvenna JP, Clark RJ, Miles JJ. Helminth immunomodulation in autoimmune disease. Front Immunol. 2017;8:453. doi:10.3389/fimmu.2017.00453.
   Google Scholar
• Correale J. Helminth/parasite treatment of multiple sclerosis. Curr Treat Options Neurol. 2014;16(6):296. doi:10.1007/s11940-014-0296-3.
   Google Scholar
• Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506–514. doi:10.1038/nrgastro.2014.66
   Google Scholar
• Dargahi N, Johnson J, Donkor O, Vasiljevic T, Apostolopoulos V. Immunomodulatory effects of probiotics: can they be used to treat allergies and autoimmune diseases? Maturitas. 2019;119:25–38. doi:10.1016/j.maturitas.2018.11.002.
   Google Scholar
• Bach J-F. The hygiene hypothesis in autoimmunity: the role of pathogens and commensals. Nat Rev Immunol. 2018;18(2):105–120. doi:10.1038/nri.2017.111.
   Google Scholar
• Calvo-Barreiro L, Eixarch H, Montalban X, Espejo C. Combined therapies to treat complex diseases: the role of the gut microbiota in multiple sclerosis. Autoimmun Rev. 2018;17(2):165–174. doi:10.1016/j.autrev.2017.11.019.
   Google Scholar
• Guarner F, Bourdet-Sicard R, Brandtzaeg P, Gill HS, McGuirk P, van Eden W, Versalovic J, Weinstock JV, Rook GA. Mechanisms of Disease: the hygiene hypothesis revisited. Nat Rev Gastroenterol Hepatol. 2006;3(5):275–284. doi:10.1038/ncpgasthep0471
   Google Scholar
• Liu Y, Alookaran J, Rhoads J. Probiotics in autoimmune and inflammatory disorders. Nutrients. 2018;10(10):1537. doi:10.3390/nu10101537.
   Google Scholar
• Morshedi M, Hashemi R, Moazzen S, Sahebkar A, Hosseinifard E-S. Immunomodulatory and anti-inflammatory effects of probiotics in multiple sclerosis: a systematic review. J Neuroinflammation. 2019;16(1):231. doi:10.1186/s12974-019-1611-4.
   Google Scholar
• Zoledziewska M. The gut microbiota perspective for interventions in MS. Autoimmun Rev. 2019;18(8):814–824. doi:10.1016/j.autrev.2019.03.016.
   Google Scholar
• Jiang J, Chu C, Wu C, Wang C, Zhang C, Li T, Zhai Q, Yu L, Tian F, Chen W. Efficacy of probiotics in multiple sclerosis: a systematic review of preclinical trials and meta-analysis of randomized controlled trials. Food Funct. 2021;12(6):2354–2377. doi:10.1039/D0FO03203D
   Google Scholar
• Kohl HM, Castillo AR, Ochoa-Repáraz J. The microbiome as a therapeutic target for multiple sclerosis: can genetically engineered probiotics treat the disease? Diseases. 2020;8(3):33. doi:10.3390/diseases8030033.
   Google Scholar
• Liu S, Rezende RM, Moreira TG, Tankou SK, Cox LM, Wu M, Song A, Dhang FH, Wei Z, Costamagna G, Weiner HL. Oral administration of mir-30d from feces of MS patients suppresses MS-like symptoms in mice by expanding Akkermansia muciniphila. Cell Host Microbe. 2019;26(6):779–794.e8. doi:10.1016/j.chom.2019.10.008
   Google Scholar
• Guarner F, Sanders ME, Eliakim R, Fedorak R, Gangl A, Garisch J, Kaufmann P, Karakan T, Khan AG, Kim N, et al. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics. World Gastroenterology Organisation. 2017. [accessed 2021 Feb 1] https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2017.pdf
   Google Scholar
• Montgomery TL, Künstner A, Kennedy JJ, Fang Q, Asarian L, Culp-Hill R, D’Alessandro A, Teuscher C, Busch H, Krementsov DN. Interactions between host genetics and gut microbiota determine susceptibility to CNS autoimmunity. Proc Natl Acad Sci USA. 2020;117(44):27516–27527. doi:10.1073/pnas.2002817117
   Google Scholar
• Miyauchi E, Kim S-W, Suda W, Kawasumi M, Onawa S, Taguchi-Atarashi N, Morita H, Taylor TD, Hattori M, Ohno H. Gut microorganisms act together to exacerbate inflammation in spinal cords. Nature. 2020;585(7823):102–106. doi:10.1038/s41586-020-2634-9
   Google Scholar
• Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct182):d5928–d5928. doi:10.1136/bmj.d5928
   Google Scholar
• Hooijmans CR, Rovers MM, De Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14(1):43. doi:10.1186/1471-2288-14-43.
   Google Scholar
• Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58(5):295–300. doi:10.1177/003591576505800503.
   Google Scholar
• Gordis L. Epidemiology.5th ed.Philadelphia (PA):Elsevier/Saunders;2014
   Google Scholar
• Mestre L, Carrillo-Salinas FJ, Feliú A, Mecha M, Alonso G, Espejo C, Calvo-Barreiro L, Luque-García JL, Estevez H, Villar LM, Guaza C. How oral probiotics affect the severity of an experimental model of progressive multiple sclerosis? Bringing commensal bacteria into the neurodegenerative process. Gut Microbes. 2020;12(1):1813532. doi:10.1080/19490976.2020.1813532
   Google Scholar
• Calvo-Barreiro L, Eixarch H, Ponce-Alonso M, Castillo M, Lebrón-Galán R, Mestre L, Guaza C, Clemente D, del Campo R, Montalban X, Espejo C. A commercial probiotic induces tolerogenic and reduces pathogenic responses in experimental autoimmune encephalomyelitis. Cells. 2020;9(4):906. doi:10.3390/cells9040906
   Google Scholar
• McMurran CE, Guzman de la Fuente A, Penalva R, Ben Menachem-Zidon O, Dombrowski Y, Falconer J, Gonzalez GA, Zhao C, Krause FN, Young AMH, et al. The microbiota regulates murine inflammatory responses to toxin-induced CNS demyelination but has minimal impact on remyelination. Proc Natl Acad Sci USA. 2019;116(50):25311–25321. doi:10.1073/pnas.1905787116
   Google Scholar
• Tankou SK, Regev K, Healy BC, Tjon E, Laghi L, Cox LM, Kivisäkk P, Pierre IV, Hrishikesh L, Gandhi R, et al. A probiotic modulates the microbiome and immunity in multiple sclerosis. Ann Neurol. 2018;83(6):1147–1161. doi:10.1002/ana.25244
   Google Scholar
• Tankou SK, Regev K, Healy BC, Cox LM, Tjon E, Kivisakk P, Vanande IP, Cook S, Gandhi R, Glanz B, et al. Investigation of probiotics in multiple sclerosis. Mult Scler. 2018;24(1):58–63. doi:10.1177/1352458517737390
   Google Scholar
• Lavasani S, Dzhambazov B, Nouri M, Fåk F, Buske S, Molin G, Thorlacius H, Alenfall J, Jeppsson B, Weström B. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. Unutmaz D, ed. PLoS ONE. 2010;5(2):e9009. doi:10.1371/journal.pone.0009009
   Google Scholar
• Sanchez JMS, Doty DJ, DePaula-Silva AB, Brown DG, Bell R, Klag KA, Truong A, Libbey JE, Round JL, Fujinami RS. Molecular patterns from a human gut-derived Lactobacillus strain suppress pathogenic infiltration of leukocytes into the central nervous system. J Neuroinflammation. 2020;17(1):291. doi:10.1186/s12974-020-01959-2
   Google Scholar
• Salehipour Z, Haghmorad D, Sankian M, Rastin M, Nosratabadi R, Soltan Dallal MM, Tabasi N, Khazaee M, Nasiraii LR, Mahmoudi M. Bifidobacterium animalis in combination with human origin of Lactobacillus plantarum ameliorate neuroinflammation in experimental model of multiple sclerosis by altering CD4+ T cell subset balance. Biomedicine Pharmacother. 2017;95:1535–1548. doi:10.1016/j.biopha.2017.08.117
   Google Scholar
• Ezendam J, De Klerk A, Gremmer ER, Van Loveren H. Effects of Bifidobacterium animalis administered during lactation on allergic and autoimmune responses in rodents: immune effects of probiotics. Clin Exp Immunol. 2008;154(3):424–431. doi:10.1111/j.1365-2249.2008.03788.x.
   Google Scholar
• Goudarzvand M, Rasouli Koohi S, Khodaii Z, Soleymanzadeh Moghadam S. Probiotics Lactobacillus plantarum and Bifidobacterium B94: cognitive function in demyelinated model. Med J Islam Repub Iran. 2016;30:391.
   Google Scholar
• Consonni A, Cordiglieri C, Rinaldi E, Marolda R, Ravanelli I, Guidesi E, Elli M, Mantegazza R, Baggi F. Administration of Bifidobacterium and Lactobacillus strains modulates experimental myasthenia gravis and experimental encephalomyelitis in Lewis rats. Oncotarget. 2018;9(32):22269–22287. doi:10.18632/oncotarget.25170
   Google Scholar
• Libbey JE, Sanchez JMS, Fleming BA, Doty DJ, DePaula-Silva AB, Mulvey MA, Fujinami RS. Modulation of experimental autoimmune encephalomyelitis through colonisation of the gut with Escherichia coli. Benef Microbes. 2020;11(7):669–684. doi:10.3920/BM2020.0012
   Google Scholar
• Secher T, Kassem S, Benamar M, Bernard I, Boury M, Barreau F, Oswald E, Saoudi A. Oral administration of the probiotic strain Escherichia coli Nissle 1917 reduces susceptibility to neuroinflammation and repairs experimental autoimmune encephalomyelitis-induced intestinal barrier dysfunction. Front Immunol. 2017;8:1096. doi:10.3389/fimmu.2017.01096
   Google Scholar
• Mangalam A, Shahi SK, Luckey D, Karau M, Marietta E, Luo N, Choung RS, Ju J, Sompallae R, Gibson-Corley K, et al. Human gut-derived commensal bacteria suppress CNS inflammatory and demyelinating disease. Cell Rep. 2017;20(6):1269–1277. doi:10.1016/j.celrep.2017.07.031
   Google Scholar
• Shahi SK, Freedman SN, Murra AC, Zarei K, Sompallae R, Gibson-Corley KN, Karandikar NJ, Murray JA, Mangalam AK. Prevotella histicola, a human gut commensal, is as potent as Copaxone® in an animal model of multiple sclerosis. Front Immunol. 2019;10:462. doi:10.3389/fimmu.2019.00462
   Google Scholar
• Shahi SK, Jensen SN, Murra AC, Tang N, Guo H, Gibson-Corley KN, Zhang J, Karandikar NJ, Murray JA, Mangalam AK. Human commensal Prevotella histicola ameliorates disease as effectively as interferon-beta in the experimental autoimmune encephalomyelitis. Front Immunol. 2020;11:578648. doi:10.3389/fimmu.2020.578648
   Google Scholar
• Maassen CBM, van Holten JCAM, Balk F, den Bak‐Glashouwer MJH, Leer R, Laman JD, Boersma WJA, Claassen E. Orally administered Lactobacillus strains differentially affect the direction and efficacy of the immune response. Veterinary Quarterly. 1998;20(sup3):81–83. doi:10.1080/01652176.1998.9694976
   Google Scholar
• Kouchaki E, Tamtaji OR, Salami M, Bahmani F, Daneshvar Kakhaki R, Akbari E, Tajabadi-Ebrahimi M, Jafari P, Asemi Z. Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Clin Nutrition. 2017;36(5):1245–1249. doi:10.1016/j.clnu.2016.08.015
   Google Scholar
• Tamtaji OR, Kouchaki E, Salami M, Aghadavod E, Akbari E, Tajabadi-Ebrahimi M, Asemi Z. The effects of probiotic supplementation on gene expression related to inflammation, insulin, and lipids in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial. J Am Coll Nutr. 2017;36(8):660–665. doi:10.1080/07315724.2017.1347074
   Google Scholar
• Ochoa-Repáraz J, Mielcarz DW, Ditrio LE, Burroughs AR, Begum-Haque S, Dasgupta S, Kasper DL, Kasper LH. Central nervous system demyelinating disease protection by the human commensal Bacteroides fragilis depends on polysaccharide a expression. JI. 2010;185(7):4101–4108. doi:10.4049/jimmunol.1001443
   Google Scholar
• Rahimlou M, Hosseini SA, Majdinasab N, Haghighizadeh MH, Husain D. Effects of long-term administration of Multi-Strain Probiotic on circulating levels of BDNF, NGF, IL-6 and mental health in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Nutr Neurosci. 2020;1–12. Published online June 5. doi:10.1080/1028415X.2020.1758887.
   Google Scholar
• Salami M, Kouchaki E, Asemi Z, Tamtaji OR. How probiotic bacteria influence the motor and mental behaviors as well as immunological and oxidative biomarkers in multiple sclerosis? A double blind clinical trial. J Funct Foods. 2019;52:8–13. doi:10.1016/j.jff.2018.10.023.
   Google Scholar
• Chen H, Ma X, Liu Y, Ma L, Chen Z, Lin X, Si L, Ma Xueying, Chen X. Gut microbiota interventions with Clostridium butyricum and norfloxacin modulate immune response in experimental autoimmune encephalomyelitis mice. Front Immunol. 2019;10:1662. doi:10.3389/fimmu.2019.01662
   Google Scholar
• Abdurasulova IN, Matsulevich AV, Tarasova EA, Kudryavtsev IV, Serebrjakova MK, Ermolenko EI, Bisaga GN, Klimenko VM, Suvorov AN. Enterococcus faecium strain L-3 and glatiramer acetate ameliorate experimental allergic encephalomyelitis in rats by affecting different populations of immune cells. Benef Microbes. 2016;7(5):719–729. doi:10.3920/BM2016.0018
   Google Scholar
• Yamashita M, Ukibe K, Matsubara Y, Hosoya T, Sakai F, Kon S, Arima Y, Murakami M, Nakagawa H, Miyazaki T. Lactobacillus helveticus SBT2171 attenuates experimental autoimmune encephalomyelitis in mice. Front Microbiol. 2018;8:2596. doi:10.3389/fmicb.2017.02596
   Google Scholar
• Kobayashi T, Kato I, Nanno M, Shida K, Shibuya K, Matsuoka Y, Onoue M. Oral administration of probiotic bacteria, Lactobacillus casei and Bifidobacterium breve, does not exacerbate neurological symptoms in experimental autoimmune encephalomyelitis. Immunopharmacol Immunotoxicol. 2010;32(1):116–124. doi:10.3109/08923970903200716
   Google Scholar
• Kwon H-K, Kim G-C, Kim Y, Hwang W, Jash A, Sahoo A, Kim J-E, Nam JH, Im S-H. Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response. Clinical Immunol. 2013;146(3):217–227. doi:10.1016/j.clim.2013.01.001
   Google Scholar
• Takata K, Kinoshita M, Okuno T, Moriya M, Kohda T, Honorat JA, Sugimoto T, Kumanogoh A, Kayama H, Takeda K, et al. The lactic acid bacterium Pediococcus acidilactici suppresses autoimmune encephalomyelitis by inducing IL-10-producing regulatory T cells. Ashour HM, ed. PLoS ONE. 2011;6(11):e27644. doi:10.1371/journal.pone.0027644
   Google Scholar
• Gharehkhani Digehsara S, Name N, Esfandiari B, Karim E, Taheri S, Tajabadi-Ebrahimi M, Arasteh J. Effects of Lactobacillus casei strain T2 (LBRC-M10783) on the modulation of Th17/Treg and evaluation of miR-155, miR-25, and IDO-1 expression in a cuprizone-induced C57BL/6 mouse model of demyelination. Inflammation. 2021;44(1):334–343. doi:10.1007/s10753-020-01339-1
   Google Scholar
• Ezendam J, Van Loveren H. Lactobacillus casei Shirota administered during lactation increases the duration of autoimmunity in rats and enhances lung inflammation in mice. Br J Nutr. 2008;99(1):83–90. doi:10.1017/S0007114507803412.
   Google Scholar
• Baken KA, Ezendam J, Gremmer ER, de Klerk A, Pennings JLA, Matthee B, Peijnenburg AACM, van Loveren H. Evaluation of immunomodulation by Lactobacillus casei Shirota: immune function, autoimmunity and gene expression. Int J Food Microbiol. 2006;112(1):8–18. doi:10.1016/j.ijfoodmicro.2006.06.009
   Google Scholar
• Kobayashi T, Suzuki T, Kaji R, Serata M, Nagata T, Ando M, Iizuka R, Tsujibe S, Murakami J, Kiyoshima-Shibata J, et al. Probiotic upregulation of peripheral IL-17 responses does not exacerbate neurological symptoms in experimental autoimmune encephalomyelitis mouse models. Immunopharmacol Immunotoxicol. 2012;34(3):423–433. doi:10.3109/08923973.2010.617755
   Google Scholar
• He B, Hoang TK, Tian X, Taylor CM, Blanchard E, Luo M, Bhattacharjee MB, Freeborn J, Park S, Couturier J, et al. Lactobacillus reuteri reduces the severity of experimental autoimmune encephalomyelitis in mice by modulating gut microbiota. Front Immunol. 2019;10:385. doi:10.3389/fimmu.2019.00385
   Google Scholar
• Johanson DM, Goertz JE, Marin IA, Costello J, Overall CC, Gaultier A. Experimental autoimmune encephalomyelitis is associated with changes of the microbiota composition in the gastrointestinal tract. Sci Rep. 2020;10(1):15183. doi:10.1038/s41598-020-72197-y.
   Google Scholar
• Zheng J, Wittouck S, Salvetti E, Franz CMAP, Harris HMB, Mattarelli P, O’Toole PW, Pot B, Vandamme P, Walter J, et al. A taxonomic note on the genus Lactobacillus: description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int J Syst Evol Microbiol. 2020;70(4):2782–2858. doi:10.1099/ijsem.0.004107
   Google Scholar
• Bsteh G, Ehling R, Lutterotti A, Hegen H, Di Pauli F, Auer M, Deisenhammer F, Reindl M, Berger T. Long term clinical prognostic factors in relapsing-remitting multiple sclerosis: insights from a 10-year observational study. Meuth SG, ed. PLoS ONE. 2016;11(7):e0158978. doi:10.1371/journal.pone.0158978
   Google Scholar
• McIvor GP, Riklan M, Reznikoff M. Depression in multiple sclerosis as a function of length and severity of illness, age, remissions, and perceived social support. J Clin Psychol. 1984;40(4):1028–1033. doi:10.1002/1097-4679(198407)40:4<1028::AID-JCLP2270400427>3.0.CO;2-1.
   Google Scholar
• Moore P, Hirsta C, Harding KE, Clarkson H, Pickersgilla TP, Robertson NP. Multiple sclerosis relapses and depression. J Psychosom Res. 2012;73(4):272–276. doi:10.1016/j.jpsychores.2012.08.004.
   Google Scholar
• Ochoa-Repáraz J, Mielcarz DW, Wang Y, Begum-Haque S, Dasgupta S, Kasper DL, Kasper LH. A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol. 2010;3(5):487–495. doi:10.1038/mi.2010.29
   Google Scholar
• Telesford KM, Yan W, Ochoa-Reparaz J, Pant A, Kircher C, Christy MA, Begum-Haque S, Kasper DL, Kasper LH. A commensal symbiotic factor derived from Bacteroides fragilis promotes human CD39 + Foxp3 + T cells and T reg function. Gut Microbes. 2015;6(4):234–242. doi:10.1080/19490976.2015.1056973
   Google Scholar
• Wang Y, Begum-Haque S, Telesford KM, Ochoa-Repáraz J, Christy M, Kasper EJ, Kasper DL, Robson SC, Kasper LH. A commensal bacterial product elicits and modulates migratory capacity of CD39 + CD4 T regulatory subsets in the suppression of neuroinflammation. Gut Microbes. 2014;5(4):552–561. doi:10.4161/gmic.29797
   Google Scholar
• Wang Y, Telesford KM, Ochoa-Repáraz J, Haque-Begum S, Christy M, Kasper EJ, Wang L, Wu Y, Robson SC, Kasper DL, Kasper LH. An intestinal commensal symbiosis factor controls neuroinflammation via TLR2-mediated CD39 signalling. Nat Commun. 2014;5(1):4432. doi:10.1038/ncomms5432
   Google Scholar
• Rolak LA. Multiple sclerosis: it’s not the disease you thought it was. Clin Med Res. 2003;1(1):57–60. doi:10.3121/cmr.1.1.57.
   Google Scholar
• Palumbo S, Pellegrini S. Experimental in vivo models of multiple sclerosis: state of the art. In: Zagon IS, McLaughlin PJ, editors. Multiple Sclerosis: perspectives in Treatment and Pathogenesis. Brisbane (AU): Codon Publications; 2017. p. 173–183. http://www.ncbi.nlm.nih.gov/books/NBK470145
   Google Scholar
• Torkildsen Ø, Brunborg LA, Myhr K-M, Bø L. The cuprizone model for demyelination. Acta Neurol Scand. 2008;117(s188):72–76. doi:10.1111/j.1600-0404.2008.01036.x.
   Google Scholar
• Dal Canto MC, Kim BS, Miller SD, Melvold RW. Theiler’s murine encephalomyelitis virus (TMEV)-induced demyelination: a model for human multiple sclerosis. Methods. 1996;10(3):453–461. doi:10.1006/meth.1996.0123.
   Google Scholar